[go: up one dir, main page]

NO20080456L - Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer - Google Patents

Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer

Info

Publication number
NO20080456L
NO20080456L NO20080456A NO20080456A NO20080456L NO 20080456 L NO20080456 L NO 20080456L NO 20080456 A NO20080456 A NO 20080456A NO 20080456 A NO20080456 A NO 20080456A NO 20080456 L NO20080456 L NO 20080456L
Authority
NO
Norway
Prior art keywords
drugs
novel
preparation
pharmaceutical compositions
ikk inhibitors
Prior art date
Application number
NO20080456A
Other languages
English (en)
Inventor
Bernard Tonnerre
Jean Wagnon
Serge Mignani
Michael Bosch
Pierre Casellas
Monsif Bouaboula
Samir Jegham
Jean-Flaubert Nguefack
Jacob-Alsboek Olsen
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0507370A external-priority patent/FR2888239B1/fr
Priority claimed from FR0511950A external-priority patent/FR2893941B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20080456L publication Critical patent/NO20080456L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Oppfinnelsen vedrører produkter med formel (I) hvori: R2, R3 og R4, representerer et hydrogen og de andre representerer hydrogen, halogen, alkyl eller alkoksy; R5 representerer hydrogen eller halogen; R1 representerer hydrogen, cykloalkyl, alkyl, alkenyl eller alkynyl, alle eventuelt substituerte; A representerer en enkel binding eller -CH2-CO-NR6-, med R6 valgt fra verdiene til R1; ringen som inneholder Y (eller ring (Y)) består av 4 til 8 ledd med Y representerende O, S, SO, SO2, N-R7 (ring (Y) som kan inneholde en karbonbro), C=O eller dioksalanet derav, CF2, CH-OR8, CH-NR8R9 og; R7 representerer hydrogen, cykloalkyl, alkyl, CH2-alkenyl eller CH2-alkynyl, alle eventuelt substituerte, R8 representerer hydrogen, alkyl, cykloalkyl eller heterocykloalkyl, alle eventuelt substituerte, der disse produktene eksiterer i alle isomere former og saltene. Oppfinnelsen vedrører også anvendelsen av de ovennevnte derivatene som medikamenter, spesielt som IKK inhibitorer.
NO20080456A 2005-07-11 2008-01-24 Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer NO20080456L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0507370A FR2888239B1 (fr) 2005-07-11 2005-07-11 Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR0511950A FR2893941B1 (fr) 2005-11-25 2005-11-25 Nouveaux derives de 2,4-dianilinopyridines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
PCT/FR2006/001619 WO2007006926A2 (fr) 2005-07-11 2006-07-06 Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk

Publications (1)

Publication Number Publication Date
NO20080456L true NO20080456L (no) 2008-03-04

Family

ID=37606288

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080456A NO20080456L (no) 2005-07-11 2008-01-24 Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer

Country Status (17)

Country Link
US (1) US20080269170A1 (no)
EP (1) EP1904479A2 (no)
JP (1) JP2009501711A (no)
KR (1) KR20080027832A (no)
AU (1) AU2006268531A1 (no)
BR (1) BRPI0613452A2 (no)
CA (1) CA2614597A1 (no)
CR (1) CR9602A (no)
EA (1) EA200800285A1 (no)
EC (1) ECSP078064A (no)
IL (1) IL188494A0 (no)
MA (1) MA29649B1 (no)
MX (1) MX2008000574A (no)
NO (1) NO20080456L (no)
NZ (1) NZ564872A (no)
TN (1) TNSN07471A1 (no)
WO (1) WO2007006926A2 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
RS51752B (sr) 2002-07-29 2011-12-31 Rigel Pharmaceuticals Metode tretiranja i prevencije autoimunih oboljenja jedinjenjima 2,4-pirimidindiamina
HRP20130602T1 (en) 2003-07-30 2013-07-31 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CA2608367C (en) 2005-06-08 2014-08-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
BRPI0617376A2 (pt) * 2005-10-13 2011-07-26 Morphochem Ag derivados de 5-quinolina tendo uma atividade antibacteriana
DK1984357T3 (da) 2006-02-17 2014-01-13 Rigel Pharmaceuticals Inc 2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
US8219697B2 (en) * 2006-05-17 2012-07-10 Oracle International Corporation Diameter protocol and SH interface support for SIP server architecture
ES2633318T3 (es) 2006-10-23 2017-09-20 Cephalon, Inc. Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met
FR2911137B1 (fr) * 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2,4-dianilinopyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911140B1 (fr) * 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911138B1 (fr) * 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2919869B1 (fr) * 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2009143389A1 (en) * 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
AU2013205510A1 (en) * 2008-05-21 2013-05-16 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
CA2819118A1 (en) * 2010-11-29 2012-06-07 Hetero Research Foundation A process for the preparation of pazopanib using novel intermediate
BR112013024378A2 (pt) 2011-03-24 2016-12-13 Chemilia Ab novos derivados de pirimidina
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Egfr発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
JP6903574B2 (ja) 2014-06-09 2021-07-14 バイオメトリー・インコーポレイテッドBiometry Inc. 検体を測定するための低コストテストストリップ及び方法
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
WO2018017699A1 (en) 2016-07-19 2018-01-25 Nolan Bryan Methods of and systems for measuring analytes using batch calibratable test strips
JP6594570B2 (ja) 2017-03-20 2019-10-23 フォーマ セラピューティクス,インコーポレイテッド ピルビン酸キナーゼ(pkr)活性化剤としてのピロロピロール組成物
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
AU2020350763A1 (en) 2019-09-19 2022-04-07 Novo Nordisk Health Care Ag Pyruvate kinase R (PKR) activating compositions
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2023212574A1 (en) * 2022-04-26 2023-11-02 Olivia Szu Hsieh Lee Nakaya Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
AU2003209077A1 (en) * 2002-02-08 2003-09-02 Smithkline Beecham Corporation Pyrimidine compounds
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
ES2365223T3 (es) * 2003-08-07 2011-09-26 Rigel Pharmaceuticals, Inc. Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
AU2004272288B2 (en) * 2003-09-18 2008-11-13 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
EP2125841A1 (en) * 2006-12-13 2009-12-02 Gilead Sciences, Inc. Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction

Also Published As

Publication number Publication date
KR20080027832A (ko) 2008-03-28
WO2007006926A2 (fr) 2007-01-18
EA200800285A1 (ru) 2008-08-29
NZ564872A (en) 2010-01-29
BRPI0613452A2 (pt) 2011-01-11
MX2008000574A (es) 2008-03-14
TNSN07471A1 (en) 2009-03-17
ECSP078064A (es) 2008-01-23
IL188494A0 (en) 2008-04-13
AU2006268531A1 (en) 2007-01-18
MA29649B1 (fr) 2008-07-01
JP2009501711A (ja) 2009-01-22
EP1904479A2 (fr) 2008-04-02
WO2007006926A3 (fr) 2007-03-22
US20080269170A1 (en) 2008-10-30
CA2614597A1 (fr) 2007-01-18
CR9602A (es) 2008-03-05

Similar Documents

Publication Publication Date Title
NO20080456L (no) Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
WO2008099072A3 (fr) Nouveaux derives de 2, 4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
CY1109765T1 (el) Αζα- δικυκλοαλκυλο αιθερες και η χρηση τους ως αγωνιστες aλφα7-nachr
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20083598L (no) Karbosykliske og heterosykliske arylsulfoner som inhibitorer av gamma-sekretase
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
AR038249A1 (es) Compuestos derivados de quinolina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos derivados en la preparacion de un medicamento
IS2734B (is) Pýrasólafleiður og notkun þar á, ásamt lyfjasamsetningum
NO20062677L (no) Benzyleteraminforbindelser anvendbare som CCR-5-antagonister
NO20061406L (no) Organiske forbindelser
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20084005L (no) Aminderivater
SE0202133D0 (sv) Novel compounds
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
AR037534A1 (es) Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios
NO20092689L (no) Quinuclidinolderivater som muskarin reseptorantagonister
AR041297A1 (es) Derivados de 4-pirrolidino- fenil- bencil eter
NO20090327L (no) Nye forbindelser 384
CY1106857T1 (el) Βενζαμιδια 4-(αμινομεθυλ)-πιπεριδινης ως 5ht4-ανταγωνιστες
NO20064579L (no) Bifenylforbindelser anvendelige som muskariniske receptorantagonister
NO20063469L (no) Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister
NO20050418L (no) Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet
AR057705A1 (es) 3-acilaminobenzanilidas insecticidas
NO20092224L (no) Quiniklidinderivater av (hetero)arylcykloheptankarboksylsyre som muskarinreseptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application